Trial Profile
PPAR Alpha (LY518674): A Phase 2 Study of the Combinatorial Effect of LY518674 and Atorvastatin in Subjects With Hypercholesterolemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs LY 518674 (Primary)
- Indications Hypercholesterolaemia
- Focus Biomarker; Therapeutic Use
- 25 Mar 2007 Results have been published
- 17 Nov 2006 Status change
- 18 Nov 2005 New trial record.